New antibody drug ESG206 tested for Hard-to-Treat blood cancers
Disease control
Terminated
This early-phase study tested a new drug called ESG206 in adults with advanced B-cell blood cancers that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. However, the study was withdrawn before any participants we…
Phase: PHASE1 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated May 14, 2026 12:02 UTC